Dasotraline Adult ADHD Study

Adult Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:
A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Status Completed

Clinical Trial Summary

This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD.

Clinical Trial Description

This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD using 2 doses of dasotraline (4 mg/day or 6 mg/day) versus placebo over an 8 week treatment period (8 weeks of active treatment followed by a 2-week withdrawal phase). ;

Study Design

Related Conditions & MeSH terms

Adult Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder with Hyperactivity
Hyperkinesis

Clinical Trial Details

NCT number	NCT02276209
Study type	Interventional
Source	Sunovion
Contact
Status	Completed
Phase	Phase 3
Start date	December 2014
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06000501` - Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening	Phase 4
Completed	`NCT03721588` - Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
Completed	`NCT03324581` - The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder	Phase 2
Active, not recruiting	`NCT06221930` - Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder	N/A
Completed	`NCT02160262` - Open-label Safety Study in Adults With ADHD	Phase 3
Completed	`NCT01692782` - Adult Attention Deficit Hyperactivity Disorder	Phase 2
Completed	`NCT01798381` - Essential Fatty Acids in Adult ADHD	Phase 3
Completed	`NCT00553319` - Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence	Phase 2/Phase 3